WuXi CFO Edward Hu will share his thoughts on early-stage venture capital funding at BIO China in November. As head of WuXi Corporate Venture Fund, Hu pays close attention to the emerging biotech sector in China, and will discuss the topic with speakers from leading organizations and venture capital firms. In our mission to bring innovation closer to patients, WuXi has invested in exciting biotechs including Foundation Medicine, Novira, and Syros.

Related Links:

Early-Stage VC Funding in China (Source: BIO)

WuXi Corprate Venture Fund Participates in Syros $30M Series A

Epizyme, Agios, and Foundation Medicine to further fund innovation  through IPO